Skip to main content

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Written by Customer Service on . Posted in Public Companies.

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

  • The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
  • This triggers the option to exercise Warrants.
  • Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) — Reference is made to the stock exchange announcement by EXACT Therapeutics AS (the “Company”, Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, on 27 January 2026, referring to the Company’s private placement completed on 3 December 2024 (the “Private Placement”), in which the participants received a right to subscribe for additional shares (the “Warrants”) following the announcement of the initial safety read-out from the phase 2 ENACT trial in locally advanced pancreatic cancer.

As announced on 27 January 2026, the positive safety read-out triggered the potential exercise of warrants issued at the financing in December of 2024. The Company is pleased to announce that GE Medical Holding AB (“GEMH”), a subsidiary of GE HealthCare Technologies Inc., has today, 5 February 2026, confirmed that it will exercise all of its 26,973,169 Warrants. The exercise of GEMH’s Warrants will result in gross proceeds of NOK 33 million to the Company. The remaining Warrants holders in the program may exercise their Warrants within 15 business days from today’s date, i.e. within 26 February 2026. Updates on the Warrants exercise will follow in due course.

“We are excited about our collaboration with EXACT Therapeutics and their important clinical milestone in the ENACT phase 2 pancreatic cancer trial,” said Karley Yoder, CEO, Comprehensive Care Ultrasound, GE HealthCare. “With the exercise of the warrants, we look forward to further unlocking the potential of EXACT’s ultrasound-activated therapy and its potential benefit for pancreatic cancer patients.”

Information in this announcement is considered inside information pursuant to EU Market Abuse Regulation (MAR) and subject to the disclosure requirements pursuant to MAR Article 17 and Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by John M. Edminson, CFO, on 08:30 (CET) 5 February 2026.

About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com

For further information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.